ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Synergy Pharmaceuticals, Inc." (SGYP) Report Updated: Jul 28, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Synergy Pharmaceuticals, Inc." (SGYP)

Rating: Sell Volatility: Moderate
Total Grade: D Industry: Biotechnology
Competitors: ANAC, CBMG, LJPC, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

"Synergy Pharmaceuticals, Inc."© quotemedia

Company Profile

Synergy Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the development of drugs to treat gastrointestinal disorders and diseases in the United States. Its lead product candidate is Plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, which is in Phase II/III clinical trials to treat gastrointestinal disorders, primarily chronic constipation. The company also develops Plecanatide for the treatment of constipation-predominant-irritable bowel syndrome. In addition, it develops SP-333, a second generation GC-C receptor analog that is in pre-clinical development stage for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis and Crohn’s disease. The company is headquartered in New York, New York.

Recent News: "Synergy Pharmaceuticals, Inc."